Cited by 16Antifungal resistance and susceptibilityFungal and yeast genetics researchFungal Plant Pathogen Control

Otilonium Bromide Exhibits Potent Antifungal Effects by Blocking Ergosterol Plasma Membrane Localization and Triggering Cytotoxic Autophagy in Candida Albicans

Open access
Zhen, Cheng, Wang, Li, Feng, Yanru, Whiteway, Malcolm, Hang, Sijin, Yu, Jinhua, Lu, Hui, Jiang, Yuanying·2024·Advanced Science

Abstract

Candidiasis, which presents a substantial risk to human well‐being, is frequently treated with azoles. However, drug‐drug interactions caused by azoles inhibiting the human CYP3A4 enzyme, together with increasing resistance of Candida species to azoles, represent serious issues with this class of drug, making it imperative to develop innovative antifungal drugs to tackle this growing clinical challenge. A drug repurposing approach is used to examine a library of Food and Drug Administration (FDA)‐approved drugs, ultimately identifying otilonium bromide (OTB) as an exceptionally encouraging antifungal agent. Mechanistically, OTB impairs vesicle‐mediated trafficking by targeting Sec31, thereby impeding the plasma membrane (PM) localization of the ergosterol transporters, such as Sip3. Consequently, OTB obstructs the movement of ergosterol across membranes and triggers cytotoxic autophagy. It is noteworthy that C. albicans encounters challenges in developing resistance to OTB because it is not a substrate for drug transporters. This study opens a new door for antifungal therapy, wherein OTB disrupts ergosterol subcellular distribution and induces cytotoxic autophagy. Additionally, it circumvents the hepatotoxicity associated with azole‐mediated liver enzyme inhibition and avoids export‐mediated drug resistance in C. albicans .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/advs.202406473

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [4]a) H. L. Choy, E. A. Gaylord, T. L. Doering, mBio 2023, 14, e0135323; 37409809 PMC10470819 b) I. G. Castro, S. P. Shortill, S. K. Dziurdzik, A. Cadou, S. Ganesan, R. Valenti, Y. David, M. Davey, C. Mattes, F. B. Thomas, R. E. Avraham, H. Meyer, A. Fadel, E. J. Fenech, R. Ernst, V. Zaremberg, T. P. Levine, C. Stefan, E. Conibear, M. Schuldiner, Elife 2022, 11, e74602. 36354737 PMC9648973 c) S. S. Sokolov, N. I. Trushina, F. F. Severin, D. A. Knorre, Biochemistry (Mosc) 2019, 84, 346. 31228926

Cited by

Sorted by citations

Authors
Zhen, C., Wang, L., Feng, Y., Whiteway, M., Hang, S., Yu, J., Lu, H., & Jiang, Y.
Affiliations
  • Tongji University (CN)
  • Concordia University (CA)
Corresponding author
  • Lu, Hui
  • Jiang, Yuanying
Venue
Advanced Science
Publisher
Wiley
Published
2024-07-12
Volume
11
Issue
35
Pages
e2406473-e2406473
ISSN
2198-3844 (ISSN-L)
OpenAlex
W4400582752
Cited by
16
References
75
Citations by year
2026: 6 · 2025: 9 · 2024: 1
FWCI
5.53
Type
journal article
Language
en
Open access
Locations
  • Advanced Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Key Research and Development Program of China (2022YFC2303004, 2021YFC2300404)
  • National Natural Science Foundation of China (82020108032)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Keywords
otilonium bromide, Candida albicans, antifungal drug repurposing, plasma membrane localization, Sec31, azole resistance, drug-drug interactions, CYP3A4 inhibition, candidiasis
MeSH terms
Quaternary Ammonium Compounds, Animals, Antifungal Agents, Autophagy, Candida albicans, Candidiasis, Cell Membrane, Ergosterol, Humans, Microbial Sensitivity Tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review